Latest News
See all →
ITM Receives U.S. FDA Fast Track Designation for ITM-94 as a Diagnostic Agent for Clear Cell Renal Cell Carcinoma
- ITM-94 forms a theranostic pair with therapeutic candidate ITM-91, targeting carbonic anhydrase IX (CAIX) in clear cell renal cell carcinoma
Garching…
Read more
ITM Announces FDA Acceptance of New Drug Application (NDA) and PDUFA Date for n.c.a. 177Lu-edotreotide (ITM-11) in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
- Prescription Drug User Fee Act (PDUFA) goal date set for August 28, 2026
Garching / Munich, Germany, November 13, 2025 - ITM Isotope Technologies…
Read more
ITM to Participate in Upcoming Investor Conferences
Garching / Munich, Germany, November 10, 2025 - ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today…
Read more
